Life expectancy in peritoneal carcinomatosis depends above all on whether the disease can be removed completely with surgery. With systemic treatment alone, published median survival is 6 to 12 months. When a complete cytoreduction (CC-0) combined with HIPEC is achieved in selected patients, those medians rise to 40-60 months, and in low-grade pseudomyxoma peritonei 10-year survival exceeds 50-70%. The gap between those two scenarios is not set by the diagnosis itself, but by the primary tumour type, the extent of disease measured with the PCI score, the patient's general condition and the experience of the centre assessing the case.
What is the life expectancy in peritoneal carcinomatosis?
There is no single figure. Published median survival ranges from 6-12 months in inoperable disease treated with systemic chemotherapy alone, to 40-60 months when a complete cytoreduction with HIPEC is achieved. In patients left with residual tumour larger than 2.5 mm after surgery, the median drops to 12-20 months, which shows how decisively the surgical result shapes prognosis. By tumour origin, pseudomyxoma peritonei is the most favourable (50-70% survival at 10 years), peritoneal mesothelioma reaches medians of 60-92 months, colorectal origin achieves 30-50% survival at 5 years against under 5% with chemotherapy alone, ovarian origin 35-55 months, and gastric origin 18-24 months in highly selected cases. These figures come from specialist-centre series and from patients who met strict selection criteria, so they cannot be extrapolated to any clinical situation. They also describe groups, never individuals.
It helps to understand what a median is: the point at which half the patients in a study are still alive, not an individual prediction. Half of those patients live longer, and some of them considerably longer. None of these figures describes what will happen to one specific person, which is why they should always be read alongside an assessment by a team that has reviewed the case.
Which factors determine prognosis?
Four factors account for most of the variability. The first is the feasibility of complete cytoreduction, the only prognostic factor that can be acted on directly and the one that carries most weight. The second is the extent of disease, measured with the PCI score: below 10 the outlook is excellent, between 10 and 20 intermediate, and above 20 it worsens markedly. The third is the primary tumour, which drives both tumour biology and response to chemotherapy. The fourth is the patient's general condition: age, comorbidities and nutritional status determine which treatments can be offered and how well they are tolerated. A fifth, external factor sits alongside them: the case volume of the treating centre. Their relative weight is not fixed: in pseudomyxoma with a high PCI, cytoreduction may still be feasible, whereas in gastric origin a PCI of 15 usually rules surgery out already.
Extensive small bowel involvement deserves a separate mention, because it is the finding that most often prevents a complete cytoreduction. General condition, by contrast, can be improved before surgery: prehabilitation and nutritional optimisation widen the group of patients who can undergo complex surgery.
Does prognosis change depending on the tumour of origin?
Yes, very substantially. Pseudomyxoma peritonei has the best course, with 10-year survival of 50-70% and results close to cure in low-grade subtypes. Peritoneal mesothelioma reaches medians of 60-92 months when treated with cytoreductive surgery and HIPEC in expert centres. Colorectal origin sits at 30-50% survival at 5 years in selected patients. Ovarian cancer shows medians of 35-55 months and tolerates a higher PCI thanks to its chemosensitivity. Gastric origin is the hardest to control, with medians of 18-24 months even under strict selection. The explanation lies in biology: each primary tumour has its own growth rate, its own pattern of peritoneal seeding and its own sensitivity to chemotherapy, and those three variables determine both whether surgery is possible and how long disease control lasts afterwards. The first thing worth establishing about any survival figure is therefore which tumour of origin it refers to, because a number borrowed from the wrong series is worse than no number at all.
This hierarchy has a practical consequence: a figure read for one tumour type cannot be transferred to another. The detail is set out in our analysis of survival by tumour origin.
How much does cytoreductive surgery with HIPEC improve prognosis?
In well selected patients the difference is measured in years, not months. Cytoreductive surgery aims to remove all visible disease from the abdomen, and HIPEC (hyperthermic intraperitoneal chemotherapy) targets the residual microscopic disease that surgery cannot reach. Patients who finish the operation with no visible residual tumour (CC-0) reach medians of 40-60 months, against 12-20 months when disease larger than 2.5 mm remains. In carcinomatosis of colorectal origin, 5-year survival rises from under 5% with systemic chemotherapy alone to 30-50% with the combined approach. The indication for HIPEC must be individualised, because not every tumour origin benefits to the same degree. Outside those settings, adding HIPEC to an incomplete cytoreduction does not improve outcomes and does add morbidity, which is why patient selection weighs as heavily as technique. The strongest available data cover pseudomyxoma, mesothelioma and selected cases of colorectal and ovarian origin.
The decisive factor is therefore not only whether surgery is performed, but who performs it. Centres carrying out more than 30 cytoreduction with HIPEC procedures a year consistently achieve better CC-0 rates, lower perioperative mortality and better long-term survival. That is why choosing the right centre and requesting a second opinion are part of the treatment itself.
What happens if surgery is not feasible?
When complete cytoreduction is not possible, prognosis then depends on controlling the disease with systemic treatment and on symptom management. Chemotherapy, targeted therapies and immunotherapy still provide control for variable periods, and in selected cases PIPAC (pressurised intraperitoneal aerosol chemotherapy) can be considered as a palliative option that reduces ascites and improves tolerance. One nuance matters: "inoperable" is not always a definitive conclusion. Sometimes it means that a particular centre does not perform this type of surgery, or that the assessment was made before neoadjuvant chemotherapy reduced the tumour burden and reopened the surgical option. Reassessment also has a time window: repeating imaging after two or three cycles of chemotherapy separates patients who respond, in whom surgery can be reconsidered, from those whose progression argues against an aggressive operation. That distinction changes management in a far from negligible share of cases.
Every year we assess cases ruled out elsewhere that turn out to be operable after reassessment with up-to-date imaging or a diagnostic laparoscopy. When they genuinely are not, supportive care and a multidisciplinary approach remain decisive in preserving quality of life.
Why do two patients with the same diagnosis follow different courses?
Because tumour biology varies between people who share the same histological diagnosis. Two colorectal-origin carcinomatoses with a similar PCI can respond in opposite ways to the same chemotherapy depending on the tumour's molecular profile, its growth rate and its pattern of spread. Add to that differences in general condition, in the functional reserve needed to tolerate several hours of surgery, and in how early the diagnosis was made. Survival figures are averages drawn from heterogeneous populations, and applying them to one individual case as though they were a date is the most common and most damaging misreading. On top of that comes the effect of treatment received up to that point: which chemotherapy line was used, how long it took to diagnose the peritoneal involvement, and whether the case was ever discussed by a board experienced in peritoneal surgery. Two clinical histories that look identical on paper rarely are in practice.
The practical implication is that prognosis is reviewed throughout the process. A good response to neoadjuvant chemotherapy, a more complete cytoreduction than expected, or a limited recurrence amenable to reoperation all change the picture. Being followed by a specialist team allows decisions to be adjusted at each of those points.
Would you like your case reviewed? At Quenet Torrent Institute we are a European referral centre for the treatment of peritoneal carcinomatosis with cytoreductive surgery and HIPEC. Request a second opinion.